Vabysmo, a cutting-edge medication, has emerged as a beacon of hope for individuals grappling with eye diseases that were once deemed challenging to manage. Developed by Roche, Vabysmo has been meticulously engineered to offer an innovative solution for patients suffering from conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME). This article, penned by an ophthalmologist at Roque Eye Clinic, aims to educate patients about Vabysmo, shedding light on its mechanism, benefits, and what one can expect during treatment.